Chee-Hoo Yip

Chee-Hoo Yip

Auto-generated profile, based on publicly available information

Chee-Hoo Yip

Affiliation Department of Biological Sciences and Biotechnology, Faculty of Science and Technology, Universiti Kebangsaan Malaysia, Selangor, Malaysia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2019 in Applied Microbiology and Biotechnology
Verified
Journal Article
Open access
CYChee-Hoo Yip
Chee-Hoo Yip
OYOrr Yarkoni
Orr Yarkoni
JAJames Ajioka
James Ajioka
KWKiew-Lian Wan
Kiew-Lian Wan
SNSheila Nathan
Sheila Nathan
Prodigiosin, a red linear tripyrrole pigment and a member of the prodiginine family, is normally secreted by the human pathogen Serratia marcescens as a secondary metabolite. Studies on prodigiosin have received renewed attention as a result of reported immunosuppressive, antimicrobial and anticancer properties. High-level synthesis of prodigiosin and the bioengineering of strains to synthesise useful prodiginine derivatives have also been a subject of investigation. To exploit the potential use of prodigiosin as a clinical drug targeting bacteria or as a dye for textiles, high-level synthesis of prodigiosin is a prerequisite. This review presents an overview on the biosynthesis of prodigiosin from its natural host Serratia marcescens and through recombinant approaches as well as highlighting the beneficial properties of prodigiosin. We also discuss the prospect of adopting a synthetic biology approach for safe and cost-effective production of prodigiosin in a more industrially compliant surrogate host.

23 June 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CYChee-Hoo Yip
Chee-Hoo Yip
SMSobina Mahalingam
Sobina Mahalingam
KWKiew-Lian Wan
Kiew-Lian Wan
SNSheila Nathan
Sheila Nathan
Prodigiosin, a red linear tripyrrole pigment, has long been recognised for its antimicrobial property. However, the physiological contribution of prodigiosin to the survival of its producing hosts still remains undefined. Hence, the aim of this study was to investigate the biological role of prodigiosin from Serratia marcescens, particularly in microbial competition through its antimicrobial activity, towards the growth and secreted virulence factors of four clinical pathogenic bacteria (methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, Salmonella enterica serovar Typhimurium and Pseudomonas aeruginosa) as well as Staphylococcus aureus and Escherichia coli. Prodigiosin was first extracted from S. marcescens and its purity confirmed by absorption spectrum, high performance liquid chromatography (HPLC) and liquid chromatography-tandem mass spectrophotometry (LC-MS/MS). The extracted prodigiosin was antagonistic towards all the tested bacteria. A disc-diffusion assay showed that prodigiosin is more selective towards Gram-positive bacteria and inhibited the growth of MRSA, S. aureus and E. faecalis and Gram-negative E. coli. A minimum inhibitory concentration of 10 μg/μL of prodigiosin was required to inhibit the growth of S. aureus, E. coli and E. faecalis whereas > 10 μg/μL was required to inhibit MRSA growth. We further assessed the effect of prodigiosin towards bacterial virulence factors such as haemolysin and production of protease as well as on biofilm formation. Prodigiosin did not inhibit haemolysis activity of clinically associated bacteria but was able to reduce protease activity for MRSA, E. coli and E. faecalis as well as decrease E. faecalis, Salmonella Typhimurium and E. coli biofilm formation. Results of this study show that in addition to its role in inhibiting bacterial growth, prodigiosin also inhibits the bacterial virulence factor protease production and biofilm formation, two strategies employed by bacteria in response to microbial competition. As clinical pathogens were more resistant to prodigiosin, we propose that prodigiosin is physiologically important for S. marcescens to compete against other bacteria in its natural soil and surface water environments.

13 March 2020 in Biochemical Society Transactions
Verified
Journal Article
Closed access
PDF file
CYChee-Hoo Yip
Chee-Hoo Yip
AGAhmad-Kamal Ghazali
Ahmad-Kamal Ghazali
SNSheila Nathan
Sheila Nathan
Burkholderia pseudomallei (Bp) is the causative agent of melioidosis, a disease of the tropics with high clinical mortality rates. To date, no vaccines are approved for melioidosis and current treatment relies on antibiotics. Conversely, common misdiagnosis and high pathogenicity of Bp hamper efforts to fight melioidosis. This bacterium can be isolated from a wide range of niches such as waterlogged fields, stagnant water bodies, salt water bodies and from human and animal clinical specimens. Although extensive studies have been undertaken to elucidate pathogenesis mechanisms of Bp, little is known about how a harmless soil bacterium adapts to different environmental conditions, in particular, the shift to a human host to become a highly virulent pathogen. The bacterium has a large genome encoding an armory of factors that assist the pathogen in surviving under stressful conditions and assuming its role as a deadly intracellular pathogen. This review presents an overview of what is currently known about how the pathogen adapts to different environments. With in-depth understanding of Bp adaptation and survival, more effective therapies for melioidosis can be developed by targeting related genes or proteins that play a major role in the bacteria's survival.

1 January 2018 in AIP Conference Proceedings
Verified
Conference Paper
Closed access
CYChee-Hoo Yip
Chee-Hoo Yip
OYOrr Yarkoni
Orr Yarkoni
JAJames Ajioka
James Ajioka
KWKiew-Lian Wan
Kiew-Lian Wan
SNSheila Nathan
Sheila Nathan

31 January 2019 in Sains Malaysiana
Verified
Journal Article
Closed access
CYChee-Hoo Yip
Chee-Hoo Yip
OYOrr Yarkoni
Orr Yarkoni
MJMario Juhas
Mario Juhas
JAJames Ajioka
James Ajioka
KWKiew-Lian Wan
Kiew-Lian Wan
SNSheila Nathan
Sheila Nathan